In the search for an immunotherapy for B-cell malignancies, the membrane protein CD20 was considered a prime target. CD20 is found on the surface of all normal B cells and on 95% of cancerous B cells.

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Rituximab, a monoclonal antibody directed against the CD20 molecule found on pre-B cells and mature B cells (but not on plasma cells), was introduced in the late 1990s for the treatment of non ...

The 61 st annual meeting of the American Society of Hematology (ASH) conducted in 2019 presented bi-specific antibodies that target CD20 on the surface of B cells and CD3 on the surface of T cells ...

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

CD20 is a non-glycosylated phosphoprotein expressed on the surface of all mature B-cells. CD20 is expressed at all stages of B cell development from pre-pre B cells through to memory cells (https ...